Biomedical Engineering Reference
In-Depth Information
Biomarker
Application
Drug*
Chapter
EGFR expression
Treatment with anti-EGFR antibodies for metastatic colorectal
cancer
Cetuximab,
panitumumab
7
EML4-ALK fusion gene
Treatment with ALK kinase inhibitor for metastatic NSCLC
Crizotinib
16
ER and/or PR
Endocrine therapy for early and metastatic breast cancer
Tomoxifen,
letrozole
5
HER2 overexpression or gene
amplification
Anti-HER2 or anthracycline-based chemotherapy for early
and metastatic breast cancer; treatment of metastatic gastric
or gastroesophageal junction adenocarcinoma
Trastuzumab,
doxorubicin
4
KRAS mutations in codon 12
or 13
Cetuximab or panitumumab is not recommended for anti-
EGFR treatment in metastatic colorectal cancer with these
mutations
Cetuximab,
panitumumab
7
MammaPrint test
Adjuvant chemotherapy plus endocrine therapy for high risk
while adjuvant endocrine therapy for low risk early node-
negative and three or few-node-positive invasive breast
cancer
Chemotherapy or
tamoxifen
14
(
Continued
)
